Association of GLP-1 Receptor Agonist Exposure with Platelet Function in Patients with Diabetes and Peripheral Artery Disease After Lower-Extremity Revascularization
- 1Division of Vascular and Endovascular Surgery, Heart and Vascular Institute, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Abstract
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiovascular outcomes in patients with type 2 diabetes and have emerging relevance in peripheral artery disease (PAD), but their association with platelet function after lower-extremity revascularization is uncertain. We evaluated whether active GLP-1RA exposure was associated with thromboelastography with platelet mapping (TEG-PM) and global hemostatic parameters in patients with diabetes and PAD. Methods: We retrospectively analyzed prospectively collected serial TEG data from adults with diabetes and PAD undergoing lower-extremity revascularization between December 2022 and December 2025. GLP-1RA exposure was defined as active use at each blood draw and treated as time-varying. Platelet outcomes were analyzed using linear mixed-effects models adjusted for nonlinear elapsed time, insulin, aspirin, clopidogrel, ticagrelor, age, sex, body mass index, renal function, coronary artery disease, and hypertension. False discovery rate (FDR) correction was applied within prespecified ADP and arachidonic acid (AA) outcome families. Results: The cohort included 178 patients contributing 462 scheduled measurements; 20 patients contributed 47 GLP-1RA-exposed measurements. At baseline, 13 of 169 patients were receiving a GLP-1RA. Adjusted GLP-1RA-associated differences were −1.98 percentage points for ADP aggregation (95% CI, −10.9 to 6.89; FDR-adjusted p = 0.815), −0.64 mm for ADP maximum amplitude (MA) (95% CI, −6.06 to 4.77; FDR-adjusted p = 0.815), −0.45 percentage points for AA aggregation (95% CI, −13.5 to 12.6; FDR-adjusted p = 0.947), and −1.63 mm for AA-MA (95% CI, −8.28 to 5.03; FDR-adjusted p = 0.947). Global TEG outcomes and GLP-1RA-by-insulin interactions were not significant. The strongest time interaction was observed for ADP-MA (omnibus p = 0.072; FDR-adjusted p = 0.145). Conclusions: No statistically significant associations were detected between active GLP-1RA exposure and pathway-specific platelet reactivity or global hemostatic parameters in this longitudinal PAD cohort. Estimates remained imprecise, and effects of potentially clinically relevant magnitude could not be excluded. The descriptive ADP-mediated temporal pattern warrants prospective evaluation in larger cohorts.
Related
- Sarcopenia and outcomes after revascularization for peripheral arterial disease: a scoping review
- Functional capacity improvement and cardiovascular events after lower extremity revascularization
- Accelerated Systemic Atherosclerosis Following Immune-Related Adverse Events in a Patient with Primary Thoracic Melanoma: A Case of Sequential Coronary and Peripheral Revascularization
- Short-Term Outcomes of Lower-Extremity Surgical Revascularization for Chronic Limb-Threatening Ischemia Among Yemeni Patients: A Prospective Observational Study
- From revascularization to multimodal integrated therapy for peripheral arterial disease: immunomodulation, metabolic correction, and tissue engineering
BibTeX
@article{bansal2026association,
title = {{Association of GLP-1 Receptor Agonist Exposure with Platelet Function in Patients with Diabetes and Peripheral Artery Disease After Lower-Extremity Revascularization}},
author = {Radha Bansal and Shezan Fouzdar and Swechha Bhatt and Shiv Patel and Vanessa Sauer and Aseman Bagheri Sheshdeh and Prajakta Lokhande and Shaidah Deghan and Anahita Dua},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218591},
url = {https://www.mdpi.com/2077-0383/15/21/8591},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association of GLP-1 Receptor Agonist Exposure with Platelet Function in Patients with Diabetes and Peripheral Artery Disease After Lower-Extremity Revascularization
AU - Radha Bansal
AU - Shezan Fouzdar
AU - Swechha Bhatt
AU - Shiv Patel
AU - Vanessa Sauer
AU - Aseman Bagheri Sheshdeh
AU - Prajakta Lokhande
AU - Shaidah Deghan
AU - Anahita Dua
PY - 2026
DA - 2026/11/04
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218591
UR - https://www.mdpi.com/2077-0383/15/21/8591
AB - Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiovascular outcomes in patients with type 2 diabetes and have emerging relevance in peripheral artery disease (PAD), but their association with platelet function after lower-extremity revascularization is uncertain. We evaluated whether active GLP-1RA exposure was associated with thromboelastography with platelet mapping (TEG-PM) and global hemostatic parameters in patients with diabetes and PAD. Methods: We retrospectively analyzed prospectively collected serial TEG data from adults with diabetes and PAD undergoing lower-extremity revascularization between December 2022 and December 2025. GLP-1RA exposure was defined as active use at each blood draw and treated as time-varying. Platelet outcomes were analyzed using linear mixed-effects models adjusted for nonlinear elapsed time, insulin, aspirin, clopidogrel, ticagrelor, age, sex, body mass index, renal function, coronary artery disease, and hypertension. False discovery rate (FDR) correction was applied within prespecified ADP and arachidonic acid (AA) outcome families. Results: The cohort included 178 patients contributing 462 scheduled measurements; 20 patients contributed 47 GLP-1RA-exposed measurements. At baseline, 13 of 169 patients were receiving a GLP-1RA. Adjusted GLP-1RA-associated differences were −1.98 percentage points for ADP aggregation (95% CI, −10.9 to 6.89; FDR-adjusted p = 0.815), −0.64 mm for ADP maximum amplitude (MA) (95% CI, −6.06 to 4.77; FDR-adjusted p = 0.815), −0.45 percentage points for AA aggregation (95% CI, −13.5 to 12.6; FDR-adjusted p = 0.947), and −1.63 mm for AA-MA (95% CI, −8.28 to 5.03; FDR-adjusted p = 0.947). Global TEG outcomes and GLP-1RA-by-insulin interactions were not significant. The strongest time interaction was observed for ADP-MA (omnibus p = 0.072; FDR-adjusted p = 0.145). Conclusions: No statistically significant associations were detected between active GLP-1RA exposure and pathway-specific platelet reactivity or global hemostatic parameters in this longitudinal PAD cohort. Estimates remained imprecise, and effects of potentially clinically relevant magnitude could not be excluded. The descriptive ADP-mediated temporal pattern warrants prospective evaluation in larger cohorts.
SN - 2077-0383
ER -